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Pseudolaric acid B (PAB) is the major constituent in pseudolarix kaempferi that has been used as an anti-fungal 
remedy in traditional Chinese medicine. We purified PAB to apparent homogeneity and showed that it exhibits 
potent growth inhibition towards a panel of cancer cell line (average IC50=1 μM). PAB also induces cell cycle 
arrest at G2-M transition, leading to apoptosis. Detail analysis of the mode-of-action revealed that cellular 
microtubule networks were disrupted by PAB treatment. Chromatin condensation was observed in PAB-treated 
cells. Nonetheless, mitotic spindles apparatus failed to form. Taken together, these data suggested that microtubules 
were destabilized by PAB treatment, resulting in mitotic arrest. On the other hand, polymerization of purified 
bovine brain tubulin is dose-dependently inhibited by PAB, suggesting that tubulin is the direct target of PAB. 
However, PAB did not displace [3H]colchicine in the competition binding assay, suggesting that PAB interacts 
with tubulin through a novel binding site. Most importantly, unlike other members of microtubule-targeting 
compounds such as colchicine and taxol, PAB circumvents multidrug resistance phenotype, and displays 
remarkable potency in cells overexpresing P-glycoprotein pump. Finally, we showed that PAB is an effective anti-
tumor agent in vivo as evaluated by the murine xenograft tumor model. 
